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The separate and combined effects of molybdate and dithiothreitol on the stability of human uterine 9 S 
estrogen receptor were studied. Maximal, short-term, protection of the 9 S estrogen receptor was achieved 
by the joint inclusion of both stabilizing agents in cytosol buffers. This molybdate-dithiothreitol-mediated 
stability was dependent on reducing agent concentration inferring sulphydryl involvement in 9 S receptor 
protection by molybdate. The study also showed that molybdate-dithiothreitol could not prevent the 
gradual decay of the 9 S estrogen receptor to the 4 S form in cytosols stored at 4°C over prolonged periods. 
Estrogen Receptor Stability MoIybdate Leupeptin Dithiothreitol 
1. INTRODUCTION 
The native 9-10 S form of the estrogen receptor 
is preserved by the inclusion of molybdate in cyto- 
solic extracts from human breast carcinoma and 
myometrium and in low ionic strength gradients 
during sedimentation studies [ 1,2]. Evidence sug- 
gests that molybdate exerts its stabilizing effect by 
inhibiting the the activity of receptor modifying en- 
zymes such as phosphatases and calcium depen- 
dent proteases [3-51. Here we illustrate the in- 
fluence of molybdate on receptor structure in the 
absence and presence of dithiothreitol and present 
data which supports the involvement of a reduced 
sulphydryl moiety in the protection of the 9 S 
estrogen receptor. 
2. MATERIALS AND METHODS 
Human myometrial cytosol was prepared as in 
[5] in phosphate (P) or phosphate-molybdate 
(PM) buffers containing 10 mM potassium dihy- 
drogen orthophosphate (Ajax Chemicals, Sydney 
NSW) at pH 7.4, without or with 20 mM sodium 
molybdate (Mallinckrodt, St Louis MO), respec- 
tively. From the phosphate-buffered cytosol a 
series of cytosols containing 1 mM dithiothreitol 
(D, Calbiochem, Carlingford VIC) and/or 20 mM 
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molybdate were prepared. The resultant cytosols, 
with buffer compositions of P, PD, PM and PMD, 
were incubated for at least 16 h at 4°C with 5 nM 
[3H]estradiol-17,& (54 Ci/mmol, Radiochemical 
Centre, Amersham). Free and loosely bound hor- 
mone was removed by charcoal adsorption prior to 
the cytosols being examined by sedimentation an- 
alysis and chromatography on columns (1.6 x 30 
cm, flow rate 30 ml/h) of Sephacryl S-300 (Phar- 
macia, Lane Cove NSW). Buffers corresponding 
to those of the cytosols were used in gradient pre- 
paration and column elution. Unless otherwise 
indicated all gradients were centrifuged in an 
MSE-75 ultracentrifuge at 145000 x g for 16 h at 
4°C using a titanium swing-out rotor. Standard 
proteins were obtained from Serva (Heidelberg) 
and Blue dextran from Pharmacia (Uppsala). 
3. RESULTS 
The individual and combined effects of molyb- 
date and dithiothreitol on the sedimentation pro- 
perties of the estrogen receptor are shown in fig. 1. 
Because ultracentrifugal analysis was initially re- 
stricted to 3 samples/run cytosols in P, PD and 
PMD buffers were examined in the first centrifuga- 
tion. The last 2 extracts were analyzed again, 
together with PM buffered cytosol, 24 h later. The 
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Fig. 1. The individual and combined effects of molyb- 
date and dithiothreitol on the sedimentation rate of the 
estrogen receptor. The stabilizing agents were added to 
a phosphate-buffered myometrial cytosol to give cyto- 
sols equilibrated in P, PD, PM and PMD buffers. (A) 
After labelling with [3H]estradiol the cytosols in P (a), 
PD (0) and PMD (m buffers were subjected to glycerol 
gradient centrifugation in the corresponding buffers. (B) 
The cytosols in PM (0). PD (0) and PMD (m buffers 
were left standing at 4°C and were treated in a similar 
manner 24 h later. Sedimentation markers: (A) aldolase 
(7.9 S) and (0) ovalbumin (3.6 S). 
profiles in fig. 1 indicate that although some en- 
hancement in the concentration of the more rapidly 
sedimenting 9 S estrogen receptor is observed on 
separate inclusion of molybdate and dithiothreitol 
a much more pronounced increase is obtained by 
the combined action of the stabilizing agents in the 
extracts. 
After deriving a 9 S: 4 S ratio for each profile 
from the respective receptor concentrations the re- 
sults of fig. 1 were expressed in semiquantitative 
form by calculating the relative increase of this 
parameter in the modified cytosols compared to 
that in the unstabilized extract (table 1, myome- 
trium 1). On average dithiothreitol effected a 
2.4-fold increase in the 9 S : 4 S ratio while molyb- 
date, by itself, was less effective in promoting 9 S 
receptor stability and produced only a 1 .Cfold rise 
Table 1 
Effect of molybdate and dithiothreitol, together or 
alone, on the 9 S : 4 S ratio of estrogen receptors (increase 
(-fold) in 9 S: 4 S ratio with respect o that observed in 
unprotected cytosol) 
Agent(s) added Myometrium no. 
1 2 3 4 5 
Dithiothreitol 2.4 1.2 2.7 1.2 1.0 
Molybdate 1.4 2.1 2.0 2.2 1.8 
Molybdate + 
dithiothreitol 3.8 3.1 11.1 4.8 2.7 
All experimental details were as in fig. 1. The 9 S:4 S 
ratios were derived from sedimentation analysis profiles 
and the increase in this parameter compared to that in 
unprotected cytosol was calculated. The results for cyto- 
sols with dithiothreitol and molybdate-dithiothreitol are 
the average of two consecutive sedimentation analyses 
on the same extracts run 24 h apart 
(table 1). In the presence of reducing agent 
however, molybdate elevated the proportion of 
9 S : 4 S estrogen receptor by an average of 3 .&fold 
(table 1). Although the degree of response to the 
stabilizing compounds was variable between ex- 
tracts from different human myometria table 1 
shows that in each case the response was maximal 
if molybdate was added with dithiothreitol. Gel 
filtration of the modified cytosols on Sephacryl 
S-300 gave results (not shown) which were consis- 
tent with the findings derived from sedimentation 
analysis. 
Stabilization of the 9 S receptor by molybdate- 
dithiothreitol, as measured by the 9 S:4 S ratio, 
appears also to be dependent on reducing agent 
concentration. Fig. 2 shows that molybdate had lit- 
tle effect on 9 S receptor stability until a threshold 
concentration of 0.1-0.2 mM had been reached for 
dithiothreitol. The 9 S: 4 S ratio was further en- 
hanced by 0.5 mM dithiothreitol, but with addi- 
tional reducing agent (1 mM) only a slightly higher 
degree of protection was observed (fig. 2). The ap- 
parent requirement for a minimum dithiothreitol 
concentration for increased 9 S receptor stability 
with molybdate is consistent with results which in- 
dicate that molybdate restricts the reducing capa- 
city of dithiothreitol (unpublished). The effective 
oxidizable concentration of 1 mM dithiothreitol in 
the presence of 20 mM molybdate, as determined 
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Fig. 2. The influence of dithiothreitol concentration on 
the ratio of 9 S:4 S estrogen receptors in molybdate 
stabilized cytosols. Dithiothreitol was added to PM buf- 
fered myometrial cytosol to give extracts with reducing 
agent at 0, 0.05, 0.1, 0.2, 0.5 and 1 mM. The receptors 
were labelled with 5 nM [3H]estradiol at 4°C for 16 h 
and the 9 S : 4 S ratios determined after centrifugation at 
237000 x g for 17 h through glycerol gradients prepared 
in the corresponding buffers. Centrifugation was carried 
out in a Beckman L-8 ultracentrifuge using an SW 55Ti 
rotor. 
by ferricyanide titration, is 0.86 mM. 0 
The repeated ultracentrifugal analysis of cyto- 
sols containing dithiothreitol, with and without 
molybdate, revealed that the 9 S: 4 S ratio was 
maintained, if not slightly increased over the 24 h 
period between runs (fig. 1). The longer term in- 
fluence of molybdate on the stability of the 9 S 
estrogen receptor in the presence and absence of 
reducing agent was monitored by Sephacryl S-300 
chromatography. An almost complete conversion 
of the larger receptor form to the smaller 4 S unit 
was observed after 9 days storage at 4°C. The time 
dependent reduction in the peak height-based 
9 S : 4 S ratio for the molybdate-stabilized cytosols 
is shown in fig. 3. The rate of this decrease was not 
influenced by reducing agent, even though the ini- 
tial concentration of the 9 S receptor was much 
higher in the extract containing dithiothreitol 
(fig. 2). 
Fig. 3. The long-term effect of molybdate, with or with- 
out dithiothreitol, on the stability of the 9 S estrogen re- 
ceptor during standing at 4°C. The stabilizing agents 
were added to phosphate-buffered myometrial cytosol to 
give cytosols equilibrated in PM (0) and PMD (0) buf- 
fers. The receptors in these cytosols were labeled with 
[3H]estradiol by overnight incubation at 4°C. A 2 ml 
aliquot of the extracts was charcoal treated to remove 
unbound hormone and chromatographed on Sephacryl 
S-300 equilibrated in the corresponding buffer. The 
stability of the 9 S estrogen receptor is expressed as the 
peak-height ratio (9 S : 4 S) of the peaks attributed to the 
sulphydryl groups in the receptor molecule [6,7]. 
Dithiothreitol protects these thiol groups and can 
reactivate estradiol binding activity lost through 
oxidation during prolonged storage in the absence 
of reducing agent at 4°C [8]. Sulphydryl groups are 
also involved in the binding of progesterone to its 
receptor [9] and in the formation of glucocorti- 
coid-receptor complexes [lo]. 
4. DISCUSSION 
The stability of the hormone-binding site in 
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9 S and 4 S receptor forms. 
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The stability of glucocorticoid binding capacity 
could be dependent not only on the maintenance of 
a reduced sulphydryl functionality but also on the 
protection of a phosphorylated component [ 111. 
Both of these conditions were ensured by the joint 
inclusion of dithiothreitol and the phosphatase 
inhibitor molybdate in glucocorticoid receptor ex- 
tracts from rat thymocytes [ll]. The results ob- 
tained here suggest hat similar requirements may 
exist for the preservation of the 9 S estrogen recep- 
tor from human uterus. In all cases examined 
molybdate and dithiothreitol together afforded the 
9 S receptor a degree of protection which signifi- 
cantly exceeded that obtained by the separate 
stabilizing action of these agents. 
The variation in response by the receptor ex- 
tracts to molybdate-dithiothreitol stabilization 
may reflect differences in sulphydryl group oxida- 
tion during cytosol preparation as well as the over- 
all reducing capacity of the cytosols. This could ex- 
plain differences in glucocorticoid receptor activa- 
tion achieved by dithiothreitol in extracts from rat 
thymocytes and L929 mouse fibroblasts [l 11. 
A number of mechanisms have been proposed 
for the molybdate-mediated changes in estrogen re- 
ceptor sedimentation rate. Since molybdate is a 
very effective phosphatase inhibitor it may prevent 
dephosphorylation and subsequent cleavage of the 
receptor [3-5,11,12]. Stabilization of the 9 S 
estrogen receptor by other known phosphatase in- 
hibitors such as fluoride, glucose-l-phosphate (un- 
published) support this concept. A mode of activ- 
ity in which molybdate precipitates Ca2+ and in- 
hibits Ca2+-activated proteolysis of the estrogen 
receptor has also been suggested [5]. A third pro- 
posal involves the inhibition of RNase activity 
directed toward a 9-10 S receptor which contains 
RNA [12]. 
Yet another possibility is that molybdate may act 
directly on the steroid receptor molecule. The re- 
quirement for reduced sulphydryl groups in the 
system suggests that a thiol(s), suitably located on 
the receptor, could be interacting with molybdate. 
Since there is generally very little change in binding 
affinity or capacity on receptor stabilization with 
molybdate [2], the reactive sulphydryl group(s) re- 
quired for 9 S receptor stability may be distinct 
from those essential for the maintenance of steroid 
binding capacity. A similar mode of interaction 
has been proposed for molybdate interference in 
progesterone receptor activation [ 13,141. Molyb- 
date has been shown to form complexes with pro- 
tein sulphydryl groups and other thiol ligands [ 151. 
Although molybdate did not inhibit the loss of 
glucocorticoid binding capacity after exogenous 
phosphatase treatment in rat liver cytosol [16], it 
allowed restoration of binding activity with dithio- 
threitol, suggesting that an interaction between 
molybdate and a sulphydryl group on the receptor 
may be important for molybdate-mediated sta- 
bility. 
The relationship between the protein structures 
responsible for the maintenance of 9 S receptor 
and hormone binding site integrity is not clear. 
Proteolytic cleavage of the 9 S cytosolic estrogen 
receptor from a number of target organs produces 
smaller discrete forms with full retention of the 
estrogen binding site [ 1,4,5,12]. Utilizing a cell-free 
system, a nuclear phosphatase has been described 
from calf uterus which appears to interact directly 
with estrogen receptors preventing the binding of 
hormone to unoccupied sites and releasing recep- 
tor-bound steroid by disruption of the receptor- 
estradiol complex [ 171. 
Failure of molybdate-dithiothreitol to ensure 
the long-term stability of the 9 S estrogen receptor 
to prolonged storage at 4°C may indicate a specific 
9 S to 4 S receptor conversion not involving de- 
phosphorylation and/or sulphydryl group oxida- 
tion [5]. Another cytosolic enzyme, capable of in- 
ducing a slow decay of the 9 S receptor to the 4 S 
unit and which is not inhibited by molybdate, may 
be involved. Two different receptor modifying en- 
zymes, one inhibited by leupeptin or antipain and 
the other by phosphoramidon or molybdate, were 
reported in rat liver [4]. 
Further research will be required to establish the 
Precise molecular basis for the molybdate-mediated 
influences on estrogen receptors. This should be 
facilitated by the purification of these important 
biological proteins from extracts in which the sta- 
bilizing agent has been included. 
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